Abiopharma

🔍 Gilson Michelle (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 20,496 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 28,962.00 | transaction_form_type: 4
• Acquired 15,340 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | shares_owned_after: 44,302.00 | transaction_form_type: 4
• Acquired 20,530 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: M | equity_swap_involved: false | shares_owned_after: 64,832.00 | transaction_form_type: 4
• Acquired 88,542 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 88,542.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 20,496 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 20,496.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 15,340 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 20,530 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-06 | Code: M | equity_swap_involved: false | shares_owned_after: 61,590.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-fourth (1/4th) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "RSU Grant Date" shall mean January 2, 2026.
• F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 2, 2024.
• F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023.
• F5: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-fourth (1/4th) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "RSU Grant Date" shall mean January 6, 2025.